Lupisulin M 30 Solution for Injection 40IU/ml is a biphasic insulin formulation containing 70% insulin isophane (NPH insulin) and 30% human insulin, designed to provide both basal and prandial glycemic control in patients with diabetes mellitus. The intermediate-acting insulin isophane component ensures a prolonged duration of action, facilitating sustained basal insulin levels, while the soluble human insulin fraction offers rapid onset to manage postprandial glucose excursions. This combination allows for improved glycemic stability with fewer injections compared to separate basal and bolus regimens. Lupisulin M 30 is indicated for the treatment of type 1 and type 2 diabetes mellitus when diet, exercise, and oral hypoglycemic agents alone do not provide adequate glycemic control. The solution is administered via subcutaneous injection, with dosing individualized based on the patient’s metabolic needs, blood glucose monitoring, and lifestyle factors. Careful titration is essential to minimize the risk of hypoglycemia, the most common adverse effect associated with insulin therapy. Patients should be educated on proper injection technique, storage conditions, and recognition of hypoglycemia symptoms. Lupisulin M 30 should not be administered intravenously or intramuscularly and is contraindicated in patients with hypersensitivity to insulin or any excipients.